Components—specifically springs used for device activation and needle retraction—play a key role in creating a flexible design. Pharma and biopharma OEMS need to engage spring suppliers at the very onset of new device planning.
 
The global injectable drug delivery market and, more specifically, the auto-injector market is booming. And that growth is predicted to continue skyrocketing through the next decade. According to a June 2016 report by Roots Analysis—a biopharmaceutical industry market research firm—the global auto-injector market is predicted to grow at a rate of more than 8% per year for the next 10 years. Another biopharma industry market research company, Mordor Intelligence, says the global injectable drug delivery market overall “… is estimated to be USD 40.5 billion for the year 2016. The market is expected to grow at a compound annual growth rate (CAGR) of about 18.1% during the forecasted period [edit.: 2016-2021] and reach USD 92.65 billion by the end of 2021.”
 
That data bears out in the real world as evidenced by increases in production at Paragon Medical. Case in point: in 2016, Paragon Medical produced 40-60 million springs across all drug delivery systems it supplies (including auto-injector devices), and in 2017, the company expects to double that figure, making 80-100 million springs.
 
With such a huge market in play, and given the range of physical properties of drugs and biologics being administered via auto-injectors, it is crucial for pharma and biopharma industry OEMs to optimize device designs to be as adaptable, and thereby as cost-effective, as possible. And that means bringing on board metal spring component manufacturers in the initial design phase.
 
Download the full white paper to read more